UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 20, 2008
RAPTOR PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Delaware | 000-50720 | 98-0379351 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
9 Commercial Blvd., Suite 200, Novato, California 94949 | ||
(Address of principal executive offices and Zip Code) | ||
| ||
Registrant’s telephone number, including area code: (415) 382-8111 | ||
| ||
Not applicable | ||
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On October 20, 2008, Raptor Pharmaceuticals Corp. (the “Company”) issued a press release announcing the initiation of patient dosing in a Phase 2a clinical trial, in collaboration with the University of California, San Diego (“UCSD”), to evaluate cysteamine bitartrate (“cysteamine”) in adolescents diagnosed with Non-alcoholic Steatohepatitis (“NASH”). NASH, a progressive form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, is one of the leading causes of cirrhosis in the U.S. UCSD is performing the Phase 2a open-label clinical study at UCSD’s General Clinical Research Center while Raptor is providing funding and clinical supplies of cysteamine.
The press release, in the form attached to this Current Report on Form 8-K as Exhibit 99.1, is incorporated by reference into this Item 8.01 in its entirety.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits |
|
|
99.1 |
| Press Release of the Company dated October 20, 2008. |
|
|
|
SIGNATURES |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
| RAPTOR PHARMACEUTICALS CORP. |
|
|
| |
|
|
| Kim R. Tsuchimoto |
Exhibit Index
Exhibit No. |
| Description |
99.1 |
| Press Release of the Company dated October 20, 2008. |
|
|
|